Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141620 · ClinicalTrials.gov registry record · Early Phase 1
n-Acetylcysteine and Cocaine
A Early Phase 1 study of Cocaine Dependence and Cocaine Abuse, sponsored by University of Kentucky.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT02141620 is a Early Phase 1 study of Cocaine Dependence and Cocaine Abuse that has completed, run by University of Kentucky. The registered enrollment target is 15 participants, below the 298-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02141620, a Early Phase 1 study of Cocaine Dependence and Cocaine Abuse, has completed, sponsored by University of Kentucky.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the initial efficacy, safety and tolerability of n-acetylcysteine as a pharmacotherapy for cocaine dependence. A rigorous, inpatient human laboratory study will be conducted in which the subjective, physiological and reinforcing effects of cocaine are evaluated during maintenance on placebo and n-acetylcysteine.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cocaine
- DRUG n-Acetylcysteine
Study Locations (1)
Kentucky
- University of Kentucky Laboratory of Human Behavioral Pharmacology - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02141620
The ClinicalTrials.gov registry entry for NCT02141620 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 298-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (95% lower). The listed sponsor is University of Kentucky, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cocaine Dependence appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02141620 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT02141620 about?
NCT02141620 is a clinical study titled "n-Acetylcysteine and Cocaine". This study will determine the initial efficacy, safety and tolerability of n-acetylcysteine as a pharmacotherapy for cocaine dependence. A rigorous, inpatient human laboratory study will be conducted in which the subjective, physiological and reinforcing effects of cocaine are evaluated during maint...
What is the current status of trial NCT02141620?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2014-05. Estimated completion is 2016-04.
What conditions does trial NCT02141620 study?
This clinical trial studies the following conditions: Cocaine Dependence, Cocaine Abuse.
What interventions are being tested in trial NCT02141620?
The interventions under investigation include: Placebo (DRUG), Cocaine (DRUG), n-Acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT02141620?
This trial is sponsored by University of Kentucky, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02141620 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals
RECRUITING · Phase 1
-
Substance Abuse Pre-Treatment Screening Study
RECRUITING
-
Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder
RECRUITING · NA
-
Clavulanic Acid for the Treatment of Cocaine Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Glutamatergic Modulation of Cocaine-related Deficits
COMPLETED · Phase 2
-
Disulfiram for Cocaine Abuse
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.